Diar Cancer Research Results

Diar, Diarrhea: Click to Expand ⟱
Source:
Type:
Diarrhea often chemotherapy induced
Scientific Papers found: Click to Expand⟱
5627- Bif,    Efficacy and Safety of Probiotics as Adjunctive Therapy in Cancer Treatment: A Comprehensive Systematic Review and Meta-Analysis
- Review, Var, NA
Diar↓, Probiotic use was associated with a significant reduction in the incidence of diarrhea

5680- BML,    Anticancer properties of bromelain: State-of-the-art and recent trends
- Review, Var, NA
*Inflam↓, anticancer, anti-edema, anti-inflammatory, anti-microbial, anti-coagulant, anti-osteoarthritis, anti-trauma pain, anti-diarrhea, wound repair.
*Bacteria↓,
*Pain↓,
*Diar↓,
*Wound Healing↑,
ERK↓, Figure 1
JNK↓,
XIAP↓,
HSP27↓,
β-catenin/ZEB1↓,
HO-1↓,
lipid-P↓,
ACSL4↑,
ROS↑,
SOD↑,
Catalase↓,
GSH↓,
MDA↓,
Casp3↓,
Casp9↑,
DNAdam↑,
Apoptosis↑,
NF-kB↓,
P53↑,
MAPK↓,
APAF1↑,
Cyt‑c↓,
CD44↓,
Imm↑, Bromelain was also studied in the innate immune system, where it could enhance and sustain the process
ATG5↑,
LC3I↑,
Beclin-1↑,
IL2↓, bromelain in vitro experiments resulted in diminished amounts of IL-2, IL-6, IL-4, G-CSF, Gm-CSF, IFN-γ,
IL4↓,
IFN-γ↓,
COX2↓, proprietary bromelain extract could decrease IL-8, COX-2, iNOS, and TNF-α without affecting cell viability.
iNOS↓,
ChemoSen↑, Bromelain may increase the cytotoxicity of cisplatin in the treatment of breast cancer as reported in 2 studies with MDA-MB-231 and 4T1 Breast Tumor cell lines
RadioS↑, The size and weight of tumors in gamma-irradiated EST-bearing mice treated with bromelain decreased significantly with a significant amelioration in the histopathological examination
Dose↝, oral bromelain administration in breast cancer patients (daily up to a dose of 7800 mg)
other↓, The role of bromelain (in combination with papain, sodium selenite and Lens culinaris lectin) has been also tested as a complementary medicine on more than 600 breast cancer patients to reduce the side effects caused by the administration of the adju

5712- Brut,    The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease
- in-vivo, IBD, NA
Diar↓, Treatment with BJe decreased the appearance of diarrhea and body weight loss.
Weight↑,
NF-kB↓, BJe reduced nuclear NF-κB translocation, p-JNK activation, the pro-inflammatory cytokines release, the appearance of nitrotyrosine and PAR in the colon and reduced the up-regulation of ICAM-1 and P-selectin.
p‑JNK↓,
ICAM-1↓,

5933- CAR,    Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model
- in-vivo, IBD, NA
*Diar↓, Carvacrol supplementation significantly reduced the incidence of diarrhea and improved the clinical and diarrhea scores in mice (p < 0.05).
*GutMicro↑, Microbiome analysis revealed a significant increase in Proteobacteria and reduction in the abundance of protective bacterial flora in antibiotic-treated and C.
*Dysb↓, Results suggest that CR could potentially be used to control gut dysbiosis and reduce C. difficile infection

5926- CAR,    An Updated Review of Research into Carvacrol and Its Biological Activities
- Review, Nor, NA - Review, AD, NA - Review, asthmatic, NA
*Inflam↓, ic, analgesic, anti-inflammatory,antioxidant, and neuroprotective effects.
*antiOx↑,
*neuroP↑, Carvacrol has exhibited notable neuroprotective effects in experimental models of cognitiveimpairment and neurodegenerative diseases
*BioAv↑, advances in encapsulation andnanotechnology have enhanced its stability and bioavailability
*toxicity↓, Compared to phenol, carvacrol and thymol exhibitsignificantly lower toxicity. This makes carvacrol a safer alternative for various applications, frombiological agents to dietary supplements [
*Pain↓, Pain-Relieving Mechanisms of Car
*TRPV3↑, , carvacrol-induced TRPV3 activation enhances lipolysis in adipocytes via theNRF2/FSP1 a
*NRF2↑,
*Ca+2↑, TRPV3 activation in distal colon epithelial cells elevates intracellular Ca²⁺ levels and stimulates ATP release, implicating carvacrol in gut physiology and signaling
*ATP↑,
*5LO↓, s, including the inhibition of angiotensin-converting enzyme 2 (ACE2), lipoxygenase(LOX), and cyclooxygenase (COX) enzyme
*COX2↓,
PGE2↓, arvacrol’s anti-inflammatory effects involve theinhibition of prostaglandin E₂ (PGE₂) production via COX-2
*hepatoP↑, Carvacrol in Hepatic Protection as Natural Antioxidant
*AntiAg↑, Carvacrol has demonstrated significant antiplatelet activity, highlighting its potential therapeutic role in preventing thrombosis
*Diar↓, s essentialoil exhibited antidiarrheal effects in castor oil-induced diarrhea models, potentially mediated bymechanisms involving Kv channel activation and Ca²⁺ channel inhibition
*cardioP↑, em as promising nutraceutical candidates for alleviatingCVD-related complicat
*other↝, Carvacrol was evaluated for its therapeutic potential in managing erectile dysfunction (ED)associated with aging
*chemoPv↑, Chemopreventive Potential of Carvacrol in Detoxification pathways
*cognitive↑, carvacrol(0.5–2 mg/kg) and thymol significantly improved cognitive function in rats
*AChE↓, potent acetylcholinesterase inhibitory activity (IC₅₀: 158.94 μg/mL)
*GastroP↑, . Gastroprotective Effects of Carvacrol and Mechanism
*eff↑, . When combined with polysorbate 80 as a surfactant, carvacrol was efficiently deliveredto embryonic tissues, maintaining bioavailability during the peri-hatching phase
*BChE↓, acrol. The essential oil rich in carvacrol showedstrong inhibitory effects on AChE and butyrylcholinesterase (BChE) [
*CRP↓, d Phase II clinical trial, asthmatic patients whoreceived 1.2 mg/kg/day of carvacrol for two months showed significant improvements in pulmonaryfunction tests and a notable reduction in C-reactive protein levek

6765- ProBio,    Probiotics
*GutMicro↑, hese mechanisms include the inhibition of the growth of pathogenic microorganisms in the gastrointestinal tract (by fostering colonization resistance, improving intestinal transit, producing antimicrobial substances, or helping normalize a perturbed
*AntiBio↑,
*pH↓, and the reduction of luminal pH in the colon
*Diar↓, Some systematic reviews and meta-analyses report that starting certain probiotic treatments within 2 days of the first antibiotic dose helps reduce the risk of antibiotic-associated diarrhea in specific patient populations.


Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   GSH↓, 1,   HO-1↓, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↑, 1,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis↑, 1,   Casp3↓, 1,   Casp9↑, 1,   Cyt‑c↓, 1,   iNOS↓, 1,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP27↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3I↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   ERK↓, 1,  

Migration(tgid=13) ⓘ

β-catenin/ZEB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL2↓, 1,   IL4↓, 1,   Imm↑, 1,   NF-kB↓, 2,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 1,   RadioS↑, 1,  

Functional Outcomes(tgid=23) ⓘ

Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Diar↓, 2,  
Total Targets: 41

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   Dysb↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   NRF2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

TRPV3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AntiAg↑, 1,   Ca+2↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   CRP↓, 1,   Inflam↓, 2,  

Cellular Microenvironment(tgid=17) ⓘ

pH↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BChE↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   GutMicro↑, 2,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   chemoPv↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   Pain↓, 2,   toxicity↓, 1,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,   Diar↓, 4,  
Total Targets: 31

Scientific Paper Hit Count for: Diar, Diarrhea
2 Carvacrol
1 Bifidobacterium
1 Bromelain
1 Bruteridin(bergamot juice)
1 probiotics
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1456  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page